Premium
Phathom Pharmaceuticals Inc (PHAT)
NASDAQ
Hot Features
Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
| Actionnaire | Type | Détenues (Réel) | % en Circulation | Valeur Marchande | Date de Reporte |
|---|---|---|---|---|---|
| Frazier Life Sciences Management, LP | Institution | 12 466 489 | 15,63% | US$ 131,33M | 2026-03-31 |
| Medicxi Ventures (UK) LLP | Institution | 7 464 572 | 9,36% | US$ 78,64M | 2026-03-31 |
| Frazier Life Sciences IX, L.P. | Institution | 5 827 416 | 7,31% | US$ 61,39M | 2025-11-01 |
| Frazier Life Sciences Public Fund, L.P. | Institution | 5 323 356 | 6,67% | US$ 56,08M | 2025-11-01 |
| Invesco Ltd. | Institution | 4 317 426 | 5,41% | US$ 45,48M | 2026-03-31 |
| BlackRock, Inc. | Institution | 4 061 996 | 5,09% | US$ 42,79M | 2026-03-31 |
| Millennium Management LLC | Institution | 4 022 909 | 5,04% | US$ 42,38M | 2026-03-31 |
| Abingworth LLP | Institution | 3 496 808 | 4,38% | US$ 36,84M | 2026-03-31 |
| Vanguard Capital Management, LLC | Institution | 2 583 636 | 3,24% | US$ 27,22M | 2026-03-31 |
| Abingworth Bioventures 8 LP | Institution | 2 061 702 | 2,59% | US$ 21,72M | 2025-08-28 |
| New Enterprise Associates, Inc. | Institution | 1 960 169 | 2,46% | US$ 20,65M | 2026-03-31 |
| 683 Capital Management, LLC | Institution | 1 850 000 | 2,32% | US$ 19,49M | 2026-03-31 |
| Ensign Peak Advisors, Inc. | Institution | 1 627 806 | 2,04% | US$ 17,15M | 2026-03-31 |
| Catalys Pacific | Institution | 1 493 854 | 1,87% | US$ 15,74M | 2026-03-31 |
| Abingworth Bioventures VII LP | Institution | 1 435 106 | 1,80% | US$ 15,12M | 2025-08-28 |
| GW&K Investment Management, LLC | Institution | 1 421 109 | 1,78% | US$ 14,97M | 2026-03-31 |
| State Street Global Advisors, Inc. | Institution | 1 386 890 | 1,74% | US$ 14,61M | 2026-03-31 |
| Wasatch Advisors LP | Institution | 1 340 916 | 1,68% | US$ 14,13M | 2026-03-31 |
| Geode Capital Management, LLC | Institution | 1 328 045 | 1,67% | US$ 13,99M | 2026-03-31 |
| Integrated Core Strategies (US) LLC | Institution | 1 255 161 | 1,57% | US$ 13,22M | 2025-12-31 |
| Mr. David Socks | Initiés | 1 220 756 | 1,53% | US$ 12,86M | 2025-04-07 |
| Nomura Investment Management Business Trust | Institution | 1 205 369 | 1,51% | US$ 12,70M | 2026-03-31 |
| Frazier Life Sciences Public Overage Fund, L.P. | Institution | 1 088 365 | 1,36% | US$ 11,47M | 2025-08-18 |
| Crestline Investors Inc. | Institution | 995 885 | 1,25% | US$ 10,49M | 2026-03-31 |
| Franklin Resources, Inc. | Institution | 994 482 | 1,25% | US$ 10,48M | 2026-03-31 |
| Frazier Life Sciences XI, L.P. | Institution | 980 286 | 1,23% | US$ 10,33M | 2025-11-01 |
| Perceptive Advisors LLC | Institution | 925 000 | 1,16% | US$ 9,74M | 2026-03-31 |
| Marshall Wace LLP | Institution | 860 692 | 1,08% | US$ 9,07M | 2026-03-31 |
| Vanguard Portfolio Management, LLC | Institution | 666 029 | 0,84% | US$ 7,02M | 2026-03-31 |
| EcoR1 Capital, LLC | Institution | 625 000 | 0,78% | US$ 6,58M | 2026-03-31 |
| Propel Bio Management, LLC | Institution | 578 886 | 0,73% | US$ 6,10M | 2026-03-31 |
| The Goldman Sachs Group, Inc. | Institution | 540 370 | 0,68% | US$ 5,69M | 2026-03-31 |
| Two Sigma Investments, LP | Institution | 482 136 | 0,60% | US$ 5,08M | 2026-03-31 |
| StepStone Group Inc. | Institution | 422 085 | 0,53% | US$ 4,45M | 2026-03-31 |
| UBS Asset Management AG | Institution | 416 159 | 0,52% | US$ 4,38M | 2026-03-31 |
| Northern Trust Global Investments | Institution | 414 956 | 0,52% | US$ 4,37M | 2026-03-31 |
| Charles Schwab Investment Management, Inc. | Institution | 409 015 | 0,51% | US$ 4,31M | 2026-03-31 |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
S'inscrire avec l'e-mail
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.
